Filana Therapeutics, Inc. Proceeds from Sale of Available-for-sale Securities
Filana Therapeutics, Inc. (FLNA) reported Proceeds from Sale of Available-for-sale Securities of $400.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-29.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2019-03-29
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2017-12-31 was $0.00.
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2017-09-30 was $0.00.
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2017-06-30 was $0.00.
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for the quarter ending 2017-03-31 was $400.00K.
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for fiscal 2017 was $400.00K.
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for fiscal 2010 was $7.41M, a 205.82% increase from fiscal 2009.
- Filana Therapeutics, Inc. proceeds from sale of available-for-sale securities for fiscal 2009 was $2.42M.
| Period end | Proceeds from Sale of Available-for-sale Securities 3 month | Proceeds from Sale of Available-for-sale Securities 6 month | Proceeds from Sale of Available-for-sale Securities 9 month | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $400.00K 10-K · filed 2019-03-29 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $0.00 derived: sum of 2 quarters · filed 2018-10-30 | $400.00K 10-Q · filed 2018-10-30 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $400.00K 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $400.00K 10-Q · filed 2018-05-09 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-08 | $7.41M 10-K · filed 2013-02-08 | ||
| 2010-09-30 | $7.41M 10-Q · filed 2011-11-03 | |||
| 2009-12-31 | $2.42M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |